Kennedy Capital Management LLC Boosts Holdings in ANI Pharmaceuticals, Inc. $ANIP

Kennedy Capital Management LLC raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 213,801 shares of the specialty pharmaceutical company’s stock after acquiring an additional 23,414 shares during the quarter. Kennedy Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $16,877,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares in the last quarter. State Street Corp lifted its holdings in ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares in the last quarter. UBS Group AG lifted its holdings in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ANI Pharmaceuticals by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock valued at $37,682,000 after buying an additional 19,258 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of ANI Pharmaceuticals by 55.4% in the fourth quarter. Deutsche Bank AG now owns 392,576 shares of the specialty pharmaceutical company’s stock valued at $30,990,000 after buying an additional 140,008 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Thomas Andrew Rowland sold 459 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the transaction, the senior vice president directly owned 38,271 shares of the company’s stock, valued at $3,031,445.91. The trade was a 1.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00. Following the completion of the transaction, the vice president directly owned 78,390 shares in the company, valued at $6,126,962.40. The trade was a 0.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 78,516 shares of company stock worth $6,154,976. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Up 0.0%

Shares of ANI Pharmaceuticals stock opened at $81.68 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $61.17 and a 52-week high of $99.50. The company has a 50 day moving average of $79.72 and a 200 day moving average of $79.42. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $1.86 billion, a P/E ratio of 20.68 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same quarter in the previous year, the firm earned $1.70 earnings per share. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.